Stock fact sheet · data as of
Jin Medical International Ltd. (ZJYL): fair value, margin of safety and Wheel Score
Healthcare · Medical - Instruments & Supplies · China · Speculative / Distressed
Is ZJYL undervalued?
Jin Medical International Ltd. (ZJYL) closed at 2.02 on 16 Oct 2026, 20% above the GLS average fair value of 1.68. Only 2 of the 5 models that produced a number value the shares above the current price. The margin of safety is negative, so the stock fails the "below fair value" rule of the Sunday Scan; a premium of this size is common for companies whose growth the models are conservative about.
There is a wide gap between GLS Growth (0.1142) and Graham Number (3.61). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files ZJYL under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for ZJYL
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 3.61 | +79% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 2.42 | +20% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 0.5992 | -70% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 0.1142 | -94% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 1.66 | -18% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 2.60 | +29% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Jin Medical International Ltd. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 4.1/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC 2.5%, ROE 4.0%, ROA 2.2% - with debt at 0.64 times equity and negative free cash flow.
Jin Medical International Ltd. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Other Products 100% (fiscal year FY2025).
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | 2.5% |
|---|---|---|---|
| GLS Moat | 4.1 / 10 | ROE | 4.0% |
| Debt / equity | 0.64 | ROA | 2.2% |
| Free-cash-flow yield | -44.0% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 17: No options
No options are listed on Jin Medical International Ltd. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 17) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 16k shares a day on a market cap of $16M, with a beta of 7.41 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 0 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 4 / 25 | -20% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 6 / 15 | moat 4.1/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 0 / 20 | 16k shares/day, $16M cap, beta 7.41 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for ZJYL in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Instruments & Supplies
The 12 companies below are the closest to Jin Medical International Ltd. by market cap within the Medical - Instruments & Supplies industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BNGO Bionano Genomics, Inc. | 1.37 | - | - | 26No options | $16M |
| FEMY Femasys Inc. | 1.74 | - | - | 24No options | $15M |
| RVP Retractable Technologies, Inc. | 0.5931 | 0.7365 | +19% | 37Weak | $18M |
| MLSS Milestone Scientific Inc. | 0.3267 | - | - | 32Weak | $30M |
| LUCY Lucyd, Inc | 0.8425 | - | - | 24No options | $7M |
| HBIO Harvard Bioscience, Inc. | 8.31 | - | - | 32No options | $38M |
| NEPH Nephros, Inc. | 3.51 | 5.34 | +34% | 39No options | $38M |
| CUPR Cuprina Holdings (Cayman) Limited Class A Ordinary Shares | 1.95 | 0.3943 | -395% | 7No options | $5M |
| POCI Precision Optics Corporation, Inc. | 4.41 | - | - | 31No options | $48M |
| DXR Daxor Corporation | 10.20 | 42.03 | +76% | 39No options | $60M |
| STXS Stereotaxis, Inc. | 1.05 | - | - | 36Weak | $105M |
| KRMD KORU Medical Systems, Inc. | 3.03 | 0.2707 | -1019% | 28Weak | $139M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ZJYL
Is ZJYL undervalued right now?
No: at 2.02 the stock trades 20% above the GLS average fair value of 1.68 (data as of 16 Oct 2026). The margin of safety is negative.
What is the Wheel Score of ZJYL and what does it mean?
ZJYL has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for ZJYL?
1.68 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Jin Medical International Ltd. report earnings next?
No upcoming earnings date is recorded for ZJYL in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does ZJYL have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on ZJYL, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.